These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 32320771)

  • 1. 5α-Reductase inhibitors in men aged 50 years or older with androgenetic alopecia: A retrospective study.
    Kang MJ; Choi JY; Sim WY; Lew BL
    J Am Acad Dermatol; 2021 Jan; 84(1):172-173. PubMed ID: 32320771
    [No Abstract]   [Full Text] [Related]  

  • 2. Sexual dysfunction with 5-alpha-reductase inhibitor therapy for androgenetic alopecia: A global propensity score matched retrospective cohort study.
    Lauck KC; Limmer A; Harris P; Kivelevitch D
    J Am Acad Dermatol; 2024 Jul; 91(1):163-166. PubMed ID: 38552905
    [No Abstract]   [Full Text] [Related]  

  • 3. Adverse Effects of 5-Alpha Reductase Inhibitor Therapy in Men With Androgenetic Alopecia: Is There Cause for Concern?
    Arias-Santiago S; Camacho-Martínez FM
    Actas Dermosifiliogr; 2016 Nov; 107(9):709-711. PubMed ID: 27436801
    [No Abstract]   [Full Text] [Related]  

  • 4. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.
    Lee S; Lee YB; Choe SJ; Lee WS
    Acta Derm Venereol; 2019 Jan; 99(1):12-17. PubMed ID: 30206635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgenetic alopecia; drug safety and therapeutic strategies.
    Motofei IG; Rowland DL; Baconi DL; Tampa M; Sârbu MI; Păunică S; Constantin VD; Bălălău C; Păunică I; Georgescu SR
    Expert Opin Drug Saf; 2018 Apr; 17(4):407-412. PubMed ID: 29363345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men's Health.
    Said MA; Mehta A
    Curr Urol Rep; 2018 Jun; 19(8):65. PubMed ID: 29909472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dutasteride in Androgenetic Alopecia: An Update.
    Arif T; Dorjay K; Adil M; Sami M
    Curr Clin Pharmacol; 2017; 12(1):31-35. PubMed ID: 28294070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
    Traish AM; Melcangi RC; Bortolato M; Garcia-Segura LM; Zitzmann M
    Rev Endocr Metab Disord; 2015 Sep; 16(3):177-98. PubMed ID: 26296373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors.
    Coskuner ER; Ozkan B; Culha MG
    Sex Med Rev; 2019 Apr; 7(2):277-282. PubMed ID: 30301703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review.
    Fertig RM; Gamret AC; Darwin E; Gaudi S
    Dermatol Online J; 2017 Nov; 23(11):. PubMed ID: 29447628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia.
    Boersma IH; Oranje AP; Grimalt R; Iorizzo M; Piraccini BM; Verdonschot EH
    Indian J Dermatol Venereol Leprol; 2014; 80(6):521-5. PubMed ID: 25382509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety.
    Dhurat R; Sharma A; Rudnicka L; Kroumpouzos G; Kassir M; Galadari H; Wollina U; Lotti T; Golubovic M; Binic I; Grabbe S; Goldust M
    Dermatol Ther; 2020 May; 33(3):e13379. PubMed ID: 32279398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride.
    Gupta AK; Charrette A
    J Dermatolog Treat; 2014 Apr; 25(2):156-61. PubMed ID: 23768246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study.
    Shanshanwal SJ; Dhurat RS
    Indian J Dermatol Venereol Leprol; 2017; 83(1):47-54. PubMed ID: 27549867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study.
    Wei L; Lai EC; Kao-Yang YH; Walker BR; MacDonald TM; Andrew R
    BMJ; 2019 Apr; 365():l1204. PubMed ID: 30971393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical evaluation of androgen receptor and nerve structure density in human prepuce from patients with persistent sexual side effects after finasteride use for androgenetic alopecia.
    Di Loreto C; La Marra F; Mazzon G; Belgrano E; Trombetta C; Cauci S
    PLoS One; 2014; 9(6):e100237. PubMed ID: 24959691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride.
    Antoniou T; Macdonald EM; Yao Z; Gomes T; Tadrous M; Ho JM; Mamdani MM; Juurlink DN;
    BMC Musculoskelet Disord; 2018 May; 19(1):160. PubMed ID: 29789004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.
    Dutta A; Panja S; Virk RK; Kim JY; Zott R; Cremers S; Golombos DM; Liu D; Mosquera JM; Mostaghel EA; Barbieri CE; Mitrofanova A; Abate-Shen C
    Eur Urol; 2017 Oct; 72(4):499-506. PubMed ID: 28385453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride.
    Jung JY; Yeon JH; Choi JW; Kwon SH; Kim BJ; Youn SW; Park KC; Huh CH
    Int J Dermatol; 2014 Nov; 53(11):1351-7. PubMed ID: 24898559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of dutasteride 0.5 mg in Korean men with androgenetic alopecia: 5-year data demonstrating clinical improvement with sustained efficacy.
    Choi S; Kwon SH; Sim WY; Lew BL
    J Dermatol; 2024 May; 51(5):684-690. PubMed ID: 38321615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.